Biopharma week in review
Clinical Trial Results Alnylam Pharmaceuticals reported positive Phase 3 results for vutrisiran in treating transthyretin amyloidosis cardiomyopathy, boosting the company’s […]
Biopharma week in review Read Post »
Clinical Trial Results Alnylam Pharmaceuticals reported positive Phase 3 results for vutrisiran in treating transthyretin amyloidosis cardiomyopathy, boosting the company’s […]
Biopharma week in review Read Post »
Patent Expirations and Generic Competition This week saw several major blockbuster drugs facing patent expirations, potentially opening the market for
DrugPatentWatch Week in Review Read Post »
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is
DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform Read Post »
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the
Updating the DrugPatentWatch Biologics Module Read Post »
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry
Generic Portfolio Management, Partnering with Brands, and Staying Competitive Read Post »
Come join me and Wendi Lau from Abbvie as we participate in an interactive roundtable discussion on pharmaceutical portfolio management.
DrugPatentWatch and Abbvie discuss Pharmaceutical Portfolio Management Read Post »
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of
Connecting Excipients with Drug Patents – New DrugPatentWatch module Read Post »
Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from
Say ‘NO’ to Bad Contracts Read Post »
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited
DrugPatentWatch featured in Inc Magazine Read Post »
Get fresh news and insights, drug patent expirations & more…